Abstracts

Rationale: we report our experience with lacosamide, a new antiepileptic drug for partial epilepsy, with a good response and tolerance as adjuntive therapy. For the minimum side effects and the efficacy, we try in children with new onset partial epilepsy. Methods: We treated 19 patients with partial epilepsy, with or without secondary generalization, after getting conventional EEG and MRI. Lacosamide was administered orally, and final dose, after a slow titration each week, ranged between 1 to 10 mg/kg/day (median dose 200 mg/day). We follow for at least 6 months measuring seizure frequency and tolerability. Results: Nineteen patients (12 boys) were treated. Mean treatment duration was 7 months (range 4 weeks to 12 months). Treatment efficacy and tolerability was asseessed each month, with seizure frequency and a chart of side effects. 11 patients maintain seizure free (57%) and 4 more having a control of more than 75% of the seizures. 4 patients (21%) dropp off, two for lack of efficacy and two for side effects. Conclusions: Lacosamide seems to be effective and well tolerated in pediatric patients with partial epilepsy as monotherapy treatment, but studies in larger series are needed to validate these findings